EviCore Turns Guardant Shield Coverage Into a State-by-State Access Play
Guardant Shield’s staged EviCore coverage highlights how diagnostics now scale through payer-by-payer access, not just FDA approval.
Updated
What is this trend?
EviCore’s staged coverage of Guardant Shield shows colorectal cancer blood tests are now winning access market by market, making payer guideline inclusion a key commercialization lever.
- Coverage is expanding by state, not all at once, creating uneven access for Shield.
- Guideline inclusion matters, but prior auth and reimbursement terms may still limit uptake.
- FDA approval alone is no longer enough; payer execution now drives commercial velocity.
- Diagnostics are being commercialized through coverage infrastructure, coding, and care-pathway fit.
What’s the latest?
EviCore’s expansion of coverage for Guardant Health’s FDA-approved Guardant Shield colorectal cancer blood test shows how access is now being operationalized in stages: effective January 1, 2027, Shie
How it developed
- Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercialization
- Reimbursement Is Shifting Diagnostics From One-Off Tests to Serial Monitoring